Cognition Disorders Completed Phase 4 Trials for Dexmedetomidine (DB00633)

Also known as: Cognition Disorder

IndicationStatusPhase
DBCOND0027877 (Cognition Disorders)Completed4
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03054857The Effect of Dexmedetomidine Infusion on Post-operative Cognitive Function and Oxidative Stress in Cardiac SurgeryPrevention